Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2018

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2018
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,137			—			—			—		$	18,137
Product revenues		—		$	7,415			—			—			7,415
Royalty and license fee income		—			78			—			—			78
		18,137			7,493			—			—			25,630
Operating costs and expenses:
Cost of clinical laboratory services		10,995			—			—			—			10,995
Cost of product revenues		—			3,562			—			—			3,562
Research and development		—			576		$	223			—			799
Selling, general and administrative		6,252			2,974			—		$	1,799			11,025
Provision for uncollectible accounts receivable		400			(4	)		—			—			396
Legal fee expense		25			19			—			1,607			1,651
Total operating costs and expenses		17,672			7,127			223			3,406			28,428

Operating income (loss)		465			366			(223	)		(3,406	)		(2,798	)

Other income (expense):
Interest		(22	)		12			—			237			227
Other		15			2			—			—			17
Foreign exchange loss		—			(462	)		—			—			(462	)
Income (loss) before income taxes	$	458		$	(82	)	$	(223	)	$	(3,169	)	$	(3,016	)

Depreciation and amortization included above	$	437		$	358		$	—		$	20		$	815

Share-based compensation included in above:
Selling, general and administrative		26		$	17			—		$	161			204
Total	$	26		$	17		$	—		$	161		$	204

Capital expenditures	$	465		$	96		$	—		$	—		$	561

Three months ended April 30, 2017
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	19,584			—			—			—		$	19,584
Product revenues		—		$	7,312			—			—			7,312
Royalty and license fee income		—			193			—			—			193
		19,584			7,505			—			—			27,089
Operating costs and expenses:
Cost of clinical laboratory services		11,334			—			—			—			11,334
Cost of product revenues		—			3,582			—			—			3,582
Research and development		—			552		$	214			—			766
Selling, general and administrative		6,118			2,745			—		$	1,671			10,534
Provision for uncollectible accounts receivable		650			(30	)		—			—			620
Legal fee expense		4			42			—			466			512
Total operating costs and expenses		18,106			6,891			214			2,137			27,348

Operating income (loss)		1,478			614			(214	)		(2,137	)		(259	)

Other income (expense):
Interest		(28	)		12			—			131			115
Other		7			(98	)		—			17			(74	)
Foreign exchange gain		—			147			—			—			147
Income (loss) before income taxes	$	1,457		$	675		$	(214	)	$	(1,989	)	$	(71	)

Depreciation and amortization included above	$	390		$	423		$	—		$	37		$	850

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Selling, general and administrative		38		$	23			—		$	146			207
Total	$	40		$	23		$	—		$	146		$	209

Capital expenditures	$	483		$	252		$	—		$	—		$	735

Nine months ended April 30, 2018
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	58,001			—			—			—		$	58,001
Product revenues		—		$	21,618			—			—			21,618
Royalty and license fee income		—			639			—			—			639
		58,001			22,257			—			—			80,258
Operating costs and expenses:
Cost of clinical laboratory services		34,767			—			—			—			34,767
Cost of product revenues		—			10,828			—			—			10,828
Research and development		—			1,690		$	668			—			2,358
Selling, general and administrative		18,454			8,487			—		$	6,045			32,986
Provision for uncollectible accounts receivable		2,000			(11	)		—			—			1,989
Legal fee expense		46			47			—			3,689			3,782
Total operating costs and expenses		55,267			21,041			668			9,734			86,710

Operating income (loss)		2,734			1,216			(668	)		(9,734	)		(6,452	)

Other income (expense):
Interest		(70	)		35			—			604			569
Other		32			10			—			44			86
Foreign exchange gain		—			143			—			—			143
Income (loss) before income taxes	$	2,696		$	1,404		$	(668	)	$	(9,086	)	$	(5,654	)

Depreciation and amortization included above	$	1,254		$	1,039		$	—		$	57		$	2,350

Share-based compensation included in above:
Selling, general and administrative		86		$	61			—		$	470			617
Total	$	86		$	61		$	—		$	470		$	617

Capital expenditures	$	1,459		$	167		$	—		$	—		$	1,626

Nine months ended April 30, 2017
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	56,979			—			—			—		$	56,979
Product revenues		—		$	21,721			—			—			21,721
Royalty and license fee income		—			933			—			—			933
		56,979			22,654			—			—			79,633
Operating costs and expenses:
Cost of clinical laboratory services		33,282			—			—			—			33,282
Cost of product revenues		—			10,411			—			—			10,411
Research and development		—			1,695		$	376			—			2,071
Selling, general and administrative		17,967			8,596			—		$	6,683			33,246
Provision for uncollectible accounts receivable		1,910			58			—			—			1,968
Legal fee expense		105			70			—			1,079			1,254
Total operating costs and expenses		53,264			20,830			376			7,762			82,232

Operating income (loss)		3,715			1,824			(376	)		(7,657	)		(2,599	)

Other income (expense):
Interest		(85	)		34			—			291			240
Other		126			(98	)		—			41			69
Foreign exchange loss		—			(308	)		—			—			(308	)
Income (loss) before income taxes	$	3,756		$	1,452		$	(376	)	$	(7,430	)	$	(2,598	)

Depreciation and amortization included above	$	1,185		$	1,432		$	—		$	75		$	2,692

Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—		$	5
Selling, general and administrative		74		$	49			—		$	473			596
Total	$	79		$	49		$	—		$	473		$	601

Capital expenditures	$	1,070		$	354		$	—		$	—		$	1,424